In summary, reports of HER2 expression, not only in pancreatic cancer, are confusing as the term ‘overexpression’ was also used for +1 HER2 immunostaining (Yamanaka et al, 1993). This evidence concerns the gene ERBB2 and pancreatic neoplasm.